

NEURONETICS

FOR IMMEDIATE RELEASE

Neuronetics Advances Commercialization of New Depression Therapy; Hires Kim Tietz as Vice President, Marketing

Malvern, PA [February 18, 2010] – Neuronetics today announced that Kim Tietz has joined its management team as Vice President, Marketing. Mr. Tietz will lead the company's efforts to accelerate market development for its NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy[®] system for the treatment of depression.

Prior to joining Neuronetics, Mr. Tietz was a VP and Partner at Dorland Global Communications. At Dorland he was integral in the commercialization of innovative new medical device and diagnostic products. His experience helping VISX successfully establish the Laser Vision Correction category has many parallels to Neuronetics' strategy for the NeuroStar TMS Therapy market.

"Kim is a strong marketer who brings a diverse skill set to Neuronetics. His experience with new market creation and understanding of the issues surrounding the integration of a new product in physician's offices will be invaluable to us," said Bruce Shook, Neuronetics' President and CEO. "Kim's experience will benefit both our company and our customers."

"NeuroStar TMS Therapy is an exciting development for the millions of people with depression for whom medication treatment is not a solution," said Kim. "I'm excited to join Neuronetics to help psychiatrists successfully integrate NeuroStar TMS into their practices."

Neuronetics' TMS Therapy[®] is a non-invasive treatment for depression in patients who have failed prior antidepressant medications*. It uses highly focused, pulsed magnetic fields to restore function in brain regions believed to be linked to depression. TMS Therapy is an outpatient procedure performed in a physician's office in 37 minutes daily for several consecutive weeks.

Treatment with the NeuroStar TMS Therapy system is now available in 31 states, in both physician offices and select hospitals, including seven of the top 10 psychiatric hospitals identified by U.S. News and World Report.

About NeuroStar TMS Therapy

The NeuroStar TMS Therapy system was cleared by the FDA in October 2008 for patients with major depression who have not adequately benefitted from prior antidepressant medication*. NeuroStar TMS Therapy is a non-systemic (does not circulate in the bloodstream throughout the body) and non-invasive (does not involve surgery) form of neuromodulation. It stimulates nerve cells in an area of the brain that is linked to depression, by delivering highly focused MRI-strength magnetic field pulses. The treatment is typically administered daily for 4-6 weeks. In an open-label clinical trial,

which is most like real world clinical practice, approximately 1 in 2 patients experienced significant improvement in symptoms, and 1 in 3 experienced complete symptom resolution. There were no systemic side effects, such as weight gain and sexual dysfunction. The most common adverse events related to treatment were scalp pain or discomfort at the treatment area during active TMS treatments. NeuroStar TMS Therapy is contraindicated in patients with metallic implants in or around the head. NeuroStar TMS Therapy efficacy was not established for patients with depression outside the FDA-cleared indication. It is available by prescription from a psychiatrist who can determine whether NeuroStar TMS Therapy is an appropriate treatment option.

Availability of NeuroStar TMS Therapy

The NeuroStar TMS Therapy system is now available at over 100 treatment centers in 31 states, in both physician offices and select hospitals, including seven of the top 10 psychiatric hospitals identified by U.S. News and World Report. For specific information on treatment locations with NeuroStar TMS Therapy, please visit www.NeuroStarTMS.com or call the Neuronetics Customer Service Center at (877) 600-7555.

About Neuronetics

Neuronetics, Inc. is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics is the leader in the development of TMS Therapy, a non-invasive form of neuromodulation. For more information, please visit www.neuronetics.com.

About Depression

Depression affects at least 14 million American adults each year. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide. Each year, more than 30,000 people in the US commit suicide, 60% of which suffer from depression. The economic burden of depression in 2000 was estimated at \$83.1 billion in the US. Women are almost twice as likely as men to suffer from depression. However, some experts feel that depression in men is under-reported. Depression has no racial, ethnic, or socioeconomic boundaries. About two-thirds of those who experience an episode of depression will have at least one other episode in their lives. Despite major advances in treating this debilitating illness, nearly 30% of patients with depression do not benefit from or are intolerant of antidepressant therapy.

Media Contact

Nancie Steinberg
Chamberlain Communications
Ph: 212-884-0667
E-mail: nsteinberg@chamberlainpr.com

*NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

NeuroStar®, NeuroStar TMS Therapy®, and TMS Therapy® are registered trademarks of Neuronetics, Inc.